NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Bild Thomas Ferber©

Lugano, Via Canova: Blick über die Riva Giocondo Albertolli auf den Luganersee MORE TOPICS 15th International Conference on Malignant Lymphoma (ICML) - , June 18-22, 2019 4th Zurich Immuno- Oncology Symposium ICML ist gemäss Michael Hallek, Köln, eine wirklich spezielle Konferenz, 22nd August, 2019, Zurich, die in den letzten 38 Jahren zusammen mit der heutigen 15 Mal stattfand. Webcasts page 6 Bedeutsam ist für Hallek auch, dass die gesamte Community an dieser Konferenz teilnimmt. Oncoletter hat die wichtigsten Links zu den Abs- WCGIC 2019 tracts zusammengestellt. Und gibt abschliessend noch eine kurze Zu- July 3-6, 2019, Barcelona, Spain sammenfassung zu den Sessions «MULTIPLE MYELOMA: EVERY YEAR A Webcasts page 7 NEW STANDARD?» und «HOW TO APPROACH CLL IN CLINICAL PRACTICE» 2nd Zurich Lung Cancer Continue on page 2 Symposium July 5, 2019, Zurich, Switzerland 22. August 2019: 4th Zurich Webcasts page 9 Immuno-Oncology Symposium EHA June 13-16, 2019, Amsterdam, Oncoletter wurde vom Comprehen- Netherland sive Cancer Center Zurich beauf- Webcasts page 12 tragt, das 4. Zürcher Immun-Onko- logie Symposium aufzuzeichnen. ASCO Wer nicht teilnehmen konnte, hat May 31-June 4, 2019, Chicago, USA über die bereitgestellten Links die Webcasts page 15 Möglichkeit, die Vorträge jetzt zu verfolgen. Congress Calendar page 20 Continue on page 6 2 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ICML 2019

PLENARY SESSION

C. Rushton, M. Alcaide, M. Cheung, N. Abstracts Conclusion: Overall, the this phase II study improved PFS in Thomas, et al. ROBUST study did not meet the primary newly diagnosed DLBCL. endpoint of PFS for R2CHOP vs placebo/ LINK TO ABSTRACT IDENTIFYING MUTATIONS ENRICHED R-CHOP in previously untreated patients IN RELAPSED‐REFRACTORY DLBCL TO with ABC‐DLBCL, although a positive DERIVE GENETIC FACTORS UNDERLY- trend favoring R2CHOP has been ING TREATMENT RESISTANCE observed in advanced stage and higher risk patients. The safety profile of P. Langerbeins, J. Bahlo, C. Rhein, H. Abstracts Conclusion: DLBCL patients R2CHOP was consistent with those of Gerwin, et al. with mutations in relapse‐enriched individual medicines, and no new safety genes are at a higher risk of treatment signals were identified with the combi- IBRUTINIB VERSUS PLACEBO IN failure. Mutations in these genes, nation. PATIENTS WITH ASYMPTOMATIC, specifically hotspot deletions, may have LINK TO ABSTRACT TREATMENT‐NAÏVE EARLY STAGE CLL: power as biomarkers to identify patients PRIMARY ENDPOINT RESULTS OF THE at a high risk of relapse and could PHASE 3 DOUBLE‐BLIND RANDO- inform on the mechanism of acquired MIZED CLL12 TRIAL resistance to components of R‐CHOP. LINK TO ABSTRACT G.S. Nowakowski, F. Hong, D.W. Scot,t Abstracts Conclusion: The results of R. Macon, et al. this study allow to conclude that ibrutinib significantly improves EFS, PFS ADDITION OF LENALIDOMIDE TO and TTNT in patients with treatment‐ R-CHOP (R2CHOP) IMPROVES OUTCO- naïve early stage CLL when compared to U. Vitolo, T.E. Witzig, R.D. Gascoyne, MES IN NEWLY DIAGNOSED DIFFUSE placebo. There were no significant D.W. Scott, et al. LARGE B‐CELL LYMPHOMA (DLBCL): differences in adverse events between FIRST REPORT OF ECOG‐ACRIN1412 A both study arms. ROBUST: First report of phase III RANDOMIZED PHASE 2 US INTER- LINK TO ABSTRACT randomized study of lenalidomide/R‐ GROUP STUDY OF R2CHOP VS R‐CHOP CHOP (R2CHOP) vs placebo/R-CHOP in previously untreated ABC‐type diffuse Abstracts Conclusion: The addition of large BCcell lymphoma lenalidomide to R-CHOP (R2CHOP) in

Abstracts from ICML 2019 presentations Introductory Press Conference

MANTLE CELL LYMPHOMA NON-CLINICAL AND EARLY CLINICAL Step forward in aggressive lymphoma DATA WITH NEW COMBINATIONS Dr. Grzegorz Nowakowski PET IMAGING Step forward in chronic lymphocytic HIGH RISK LARGE B-CELL LYMPHOMAS leukemia treatment PEDIATRIC LYMPHOMA Prof. Dr. Michael Hallek HODGKIN LYMPHOMA Gene therapy of lymphomas and RESULTS FROM SINGLE AGENT TRIALS Liquid Biopsy FOLLICULAR LYMPHOMA Prof. Dr. Davide Rossi ONGOING TRIALS EXTRANODAL LYMPHOMAS DLBCL: CLINICAL DATA NEW DATA ON T-CELL AND OTHER CLL LYMPHOMAS

TREATMENT WITH NOVEL ANTIBODIES ADVANCES IN CAR T-CELL TREATMENT

T-CELL LYMPHOMAS NEW DRUG COMBINATIONS

CLL AND MORE INDOLENT NON-FOLLICULAR LYMPHOMA

LYMPHOMA PATHOLOGY CHEMOTHERAPY-FREE STRATEGIES

Continue on page 3 3 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Continued: ICML 2019

Continue on page 4 4 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Continued: ICML 2019

Continue on page 6

Oncoletter wird von der Nationalen Strategie gegen Krebs (NSK) seit Februar 2016 als federführende Organisation auf ihrer Homepage aufgeführt.

6 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Continued: ICML 2019

HOW TO APPROACH CLL IN CLINICAL PRACTICE Michael Hallek, Universität zu Köln (Summary from slides presented: Treatment algorithm)

CLL first line treatment (updated June 2019) Stage Del(17p) Fitness IGVH Therapy or p53mut Binet A-B, Rai =- Irrelevant Irrelevant Irrelevant None II, inactive disease Active disease or Yes Irrelevant Irrelevant Ibrutinib or Venetoclax + Obinutuzumab or Idelalisib Binet C or Rai + III-IV Rituximab (if contraindications for Ibrutinib)* No Go go M FCR (BR above 65 years) or Ibrutinib* U Ibrutinib or FCR (BR above 65 years)* Slow go M Venetoclax + Obinutuzumab or Chlorambucil + Obinutuzumab or Ibrutinib* U Venetoclax + Obinutuzumab or Ibrutinib or Chlorambucil + Obinutuzumab*

* Consider and discuss with patient: long-term vs fixed (6-12m) duration therapy, lack of convincing evidence of overall survival differences, specific side effects of each therapeutic option (myelosuppression, infections, secondary malignancies for CIT; cardiac toxicity, bleeding and autoimmune disease for Ibru; TLS and infections for Ven-Obi; autoimmune disease (diarrhea) and opportunistic infections for Idelalisib).

CLL 2nd line treatment 2019 Response to 1st line therapy Fitness Therapy Refractory or progress within 3 years Go go Change to one of the following options: Ibrutinib, Idelalisib + R, Venetoclax + Rituximab, FA, FCR (after BR), Venetoclax, A- Dex, Lenalidomide (+R), BR (after FCR). Discuss consolidation with allogeneic SCT. Slow go Change to one of the following options: Ibrutinib, Idelalisib + R, Venetoclax (+ Rituximab), A, FCR-lite, BR, Lenalidomide (+R), Ofatumumab, HD R. Progress after 3 years All Repetition of 1st line therapy is possible

4th Zurich Immuno-Oncology Symposium 2019 Dear colleagues PROGRAMM Immune Checkpoint Inhibition: Patrick Roth

We invite you to take part in the 4th Therapeutic Developments I Challenges in Optimizing Treatment Zürich Immuno-Oncology Symposium Melanoma: Bart Neyns; Combining Immune Checkpoint Inhibition recorded by ONCOLETTER & organized Chest Tumors: Rolf Stahel; with Targeted Therapy: Ross Soo; by the Comprehensive Cancer Center Head and Neck Cancer: Kevin Harrington Combining Immune Checkpoint Inhibition Zürich where a panel of renowned with Radiotherapy: Matthias Guckenberger; national and international experts will Therapeutic Developments II Moving Beyond PD-L1 / PD1 Targeting: Stefan Zimmermann provide you with an overview of the CNS Tumor: Michael Weller; Genitourinary Malignancies: Lewis Au; field. Hemato-Oncology: Markus Manz Cell-based Therapies TIL-Cells: John Haanen; Prof. Dr. Rolf Stahel, Chair Challenges in Patient Management Car-T-Cells: Hermann Einsele Comprehensive Cancer Center Zürich The Issue of Steroid Use with Immune Checkpoint Inhibition: Alessandra Curioni; Keynote Address Prof. Dr. Michael Weller, Directorate Microbiome, Proton Pump Inhibitors and Single Cell Screening in Precision Medici- Comprehensive Cancer Center Zürich Management of Gastrointestinal Toxicity: ne: Burkhard Becher Lisa Derosa; Immune related Neurological Toxicity of Link to Presentations 7 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

ESMO 21st World Congress on Gastrointestinal Cancer (WCGIC) July 3-6, 2019 - Barcelona According to the organizers, the ESMO 21st World Congress on Gastrointestinal Cancer represents the year’s most important gathering designed to focus on reversing the current global statistics that rank gastrointestinal malignancies as the leading causes of cancer deaths worldwide. Oncoletter is providing you with the most important news from the conference and with useful links to more information on the conference website such as abstracts and session links.

Choice of important papers presented at the daily WCGIC press conferences

Wednesday, 3 July, Opening Press Conference: Pancreatic Cancer is rising for unknown reasons; Patients living with metastatic colorectal cancer: what are their most pressing needs? An international survey (Abstract PD-023); ESMO World GI Cancer 2019: what to look out for:

Thursday, 4 July:

Continue on page 8 8 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Continued: ESMO 21st WCGIC

Friday, 5 July:

Comments on TAGS by Eric Van Cutsem, Josep Tabernero and Julien Taieb

Continue on page 9 9 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

Continued: ESMO 21st WCGIC

Statement Julien Taieb: See also statements by Gerald Prager, Vienna, on two studies (APACT & POLO) and on treatment options for pancreatic cancer presented at the ESMO-GI:

Do you remember this sight? If not, check out WCGIC 2020 in Barcelona from 1 to 4 July Second Zurich Lung Cancer Symposium July 5, 2019, University Hospital Zurich

Since 8 years, the Thoracic Oncology Center is a strong pillar of the Comprehensive Cancer Cancer Center Zürich. We could con- tribute to and witness the extraordinary advances in the diagnosis and treatment of lung cancer. Lung cancer screening is beco- ming a promising method to prevent cancer-related mortality and surgical techniques have been refined addressing small lesions as well as locally advanced disease. In the same time, stereotactic radiotherapy has revolutionized the field of radio-oncology providing results unheard in the past. Molecular pathology and PET-imaging have become an intricate part of lung cancer diag- nostics and patients are profiting from staggering advances in personalized therapy and therapy with immune checkpoint inhibi- tors. With this symposium, which had been recorded by ONCOLETTER, the Thoracic Oncology Center will demonstrate the colla- borative spirit within our Center, give an overview on current and evolving standards of diagnosis and treatment and highlight the considerable advances in personalized therapy and immunotherapy, as well as the fruitful exchange with our colleagues at the Shanghai Chest Hospital. Der erste und einzige CDK4/6-Hemmer mit kontinuirlicher Gabe1,*,**

NEU: Verzenios® (Abemaciclib) auch in Kombination mit Aromatase-Hemmer erstattet6

Verzenios® ist angezeigt zur Behandlung von post-menopausalen Frauen mit HR+, HER2- lokal fortgeschrittenem oder metastasiertem Brustkrebs.1

VERZENIOS® JETZT MIT DER BREITESTEN RÜCKERSTATTUNG6,7,8 ÜBER ALLE THERAPIELINIEN1

VERZENIOS® VERZENIOS® + MONOTHERAPIE FULVESTRANT VERZENIOS® + AROMATASE-HEMMER

Vorteile von Verzenios® für Ihre Patienten • Hohe Ansprechrate, verbessertes PFS2,3,4 • Kontinuierliche Gabe1,*,** • Gut handhabbares Nebenwirkungsprofil1,5 • Kombination mit AI (z.B. Letrozol, Anastrozol) zugelassen1 und erstattet6

Eli Lilly (Suisse) S.A. 16, Ch. des Coquelicots, CH -1214 Vernier (GE)

12 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

24th Congress of EHA - The European Hematology Association Amsterdam, June 13 - 16, 2019

The EHA Annual Congress is a forum for original unpublished data, for sharing ideas about haematological innovation, as well as for disseminating evidence-based knowledge of prima- ry clinical relevance. Oncoletter - like a quick guide - provides you with a choice of some of the important clinical studies (with links leading to the EHA abstracts) presented at the 24th EHA in Amsterdam.

Presidential Symposium LINK Hodgkin lymphoma - LINK New therapies in AML LINK

Late-breaking oral presentations Novel agents and therapies for Gene therapy, cellular immuno- (6 best abstracts) LINK CLL LINK therapy and vaccination - Biolo- gy & translational research LINK Important presentations at Press New stratification and treatment BriefingsLINK approaches in ALL - including Gene therapy, cellular immuno- CAR T Cell therapy LINK therapy and vaccination LINK Indolent and mantle-cell non- Hodgkin Lymphoma - LINK Advances in the management of Update on clinical trials in MPN LINK thalassemia LINK Aggressive lymphomas - New LINK agents LINK Immunotherapy in relapsed/ New agents in MPN refractory multiple myeloma LINK Aggressive lymphomas - First line, combination therapy & real- Novel agents for newly diag- If you like to see which studies life data - Aggressive non-Hodg- nosed plasma cell dyscrasias EHA has chosen as the most kin lymphoma LINK LINK important oral presentations including also biology & trans- Novel strategies in multiple Myeloma and other monoclonal lational research please refer myeloma LINK gammopathies - LINK to this LINK.

Continued page 13 13 Continued 24th EHA

Important studies presented at the EHA Press Briefing, Friday, June 14, 2019

Webcasts from presentations may be watched on the oncoletter website by clicking WEBCAST

| PHASE 3 RANDOMIZED STUDY OF ency does not impair systemic iron duration of 8.5 months (range 1.8-32.4). DARATUMUMAB + BORTEZOMIB/ homeostasis, here we demonstrate that The 24-week TI rate was 26%. HI-E rate THALIDOMIDE/DEXAMETHASONE deletion of a single Tfr2 allele in the BM was 68%. All patients with IPSS-R (D-VTD) VERSUS VTD IN TRANSPLANT- is sufficient to improve the hematologi- intermediate and poor cytogenetic risk ELIGIBLE NEWLY DIAGNOSED MULTIP- cal parameters of thalassemic mice. responded. Biomarker analyses of LE MYELOMA: PART 1 CASSIOPEIA This finding paves the way toward a telomerase activity and mutation allele RESULTS potential targeted therapy based on par- burden indicate an effect on the (abstract S874) - Presenter: tial Tfr2 inhibition that might be malignant mutant clone. These data Dr Philippe Moreau – France beneficial for thalassemia (and potenti- support Part 2 of IMerge, Phase 3 place- ally for other forms of anemia) without bo-controlled, randomized portion of Conclusion: D-VTd in induction prior to inducing defective hepcidin activation the study, expected to open mid-2019. and consolidation after ASCT improved and iron overload. In addition, our depth of response (sCR, ≥CR, and MRD results prove that targeting Tfr2 in negativity) and PFS with acceptable combination with an anti-TMPRSS6 | Labor is the most frequent outcome in safety. The favorable benefit-risk profile therapy may be a valuable therapeutic the European Leukemia Net registry of supports the use of D-VTd in transplant- approach that strongly improves the patients with chronic myeloid leukemia eligible NDMM. CASSIOPEIA is the first thalassemic phenotype. However, and pregnancy (abstract S881) - Pre- study to demonstrate the clinical benefit Tmprss6 inhibition must be tightly senter: Dr Ekaterina Chelysheva – Rus- of daratumumab plus standard of care controlled to avoid excessive iron sian Federation in transplant-eligible NDMM patients. restriction. Further experiments will allow setting up the optimal conditions. Conclusion: Most pregnancies in CML See also: THE LANCET, VOLUME 394, female pts resulted in normal childbirth ISSUE 10192, P29-38, JULY 06, 2019 with no increased rate of birth abnor- | Treatment with Imetelstat Provides malities in spite of TKI use at conception Durable Transfusion Independence in even if treatments were mostly early | Results from the Randomized, Heavily Transfused Non-Del(5q) Lower stopped at implant (4-5 weeks). Placebo-Controlled, Phase 3 Hemoglo- Risk MDS Relapsed/Refractory to Different therapies were used during bin Oxygen Affinity Modulation to erythropoietic stimulating agents pregnancy when needed. The results in Inhibit HbS Polymerization (HOPE) (abstract S837) - Presenter: terms of conception/pregnancy may be Trial of Voxelotor in Adults and Dr Pierre Fenaux – France valuable for the development of CML Adolescents with Sickle Cell Disease treatment schemes particularly (abstract S147) Presenter: Conclusion: In high RBC transfusion considering the variety of disease Dr Jo Howard – United Kingdom burden patients with non-del(5q) status. LR-MDS R/R to ESA and naive to LEN/ Conclusion: Voxelotor treatment HMA, single-agent imetelstat yielded demonstrated a dose-dependent increa- 8-week TI rate of 45%, with a median Continued page 14 se in Hb, with the majority of patients on voxelotor 1500 mg achieving a >1.0-g/dL improvement in Hb from baseline to Looking for key topics presented at EHA24? Or did you miss a topic week 24. In addition, there was a discussed at the congress? dose-dependent decrease in measures of hemolysis with voxelotor. Furthermo- re, voxelotor was generally well Click on a section title below to see what topics are covered in the con- tolerated. These results suggest that gress report: voxelotor has the potential to be disease-modifying by improving anemia Topics-in-Focus | Hemoglobinopathies and reducing hemolysis and their Topics-in-Focus | Immunotherapy associated morbidity and mortality. Benign disorders Myeloid malignancies Lymphoid malignancies and plasma cell disorders | Double targeting of abnormal Stem cell transplantation and special therapy erythropoiesis strikingly improves anemia in a thalassemia mouse model Laboratory diagnosis (abstract S148) - Presenter: Thrombosis and hemostasis Dr Antonella Nai – Transfusion medicine Special sessions Conclusion: While Tfr2 haploinsuffici- 14 Continued 24th EHA

Important studies presented at the EHA Press Briefing, Saturday, June 15, 2019

Webcasts from presentations may be watched on the oncoletter website by clicking WEBCAST

| Burning out the T-ALL engine: NADK | A Phase 3 Study of Venetoclax or is a new therapeutic target in T-cell Placebo in Combination with Bortezo- Acute Lymphoblastic Leukaemia mib and Dexamethasone in Patients (abstract S857) Presenter: with Relapsed/Refractory Multiple Dr Etienne De Braekeleer – United Myeloma Kingdom (abstract LB2601) Presenter: Dr Shaji Kumar- United States of Conclusion: Our findings propose that America the intracellular domain of NOTCH1 activates NADK to enhance the produc- Conclusion: Although the addition of tion NADP+/NADPH, a function required Ven to Bd significantly improved PFS, to support it proliferative effects. This ORR, ≥VGPR, and uMRD rates, the frames NADK as a putative novel increased risk of death results in an therapeutic vulnerability of NOTCH1- unfavorable benefit-risk profile in a driven T-ALL and potentially other broad population. In t(11;14) pts, in NOTCH1-driven cancers. addition to improvements in PFS, a positive trend in OS with Ven was observed, suggesting that a biomarker- driven approach with Ven may be most | Overcoming the “Don’t Eat Me” Signal appropriate in MM. of Refractory Lymphomas (abstract S867) Presenter: Dr Mark Roschewski – United States of America | Acalabrutinib significantly prolongs Conclusion: 5F9+rituximab is a novel time patients live with previously immunotherapy blocking a key macro- treated CLL without their disease phage/cancer checkpoint. It is well progressing tolerated with rapid and durable (abstractLB2606) - Presenter: responses observed in both heavily Dr Paolo Ghia - Italy pre-treated DLBCL and indolent lymphoma patients. Ph2 enrollment is Conclusion: Acalabrutinib monotherapy ongoing (NCT02953509). Funded by significantly improved PFS with a more Forty Seven and the Leukemia and tolerable safety profile compared with Lymphoma Society. IdR/BR in pts with R/R CLL.

Continued EHA Press Briefing, Friday, June 14

| Introduction of a new fixed-duration | Genomic evidence of residual disease See you at the next EHA in Frank- targeted therapy with venetoclax plus in patients in remission prior to stem furt, Germany obinutuzumab in previously untreated cell transplant; fate or opportunity for patients with chronic lymphocytic early intervention? (abstract LB2600) - June 11 - 14, 2020 leukemia (CLL) and coexisting comor- Presenter: Dr Christopher Hourigan - bidities United States of America The congress will take place at the (abstract S149) - Presenter: Dr Kirsten Messe Frankfurt Venue at Ludwig- Fischer – Germany Conclusion: Detection of an AML-asso- Erhard-Anlage 1, 60327, Frankfurt am ciated variant using ultra-deep next- Main, Germany. LINK Conclusion: Fixed-duration VenG generation DNA sequencing in the blood induced deep, high (<10-4 in 3/4 of pts of AML patients in CR prior to alloHCT and <10-6 in 1/3 of pts), and long lasting was associated with increased relapse MRD-negativity rates (with a low rate of rate and inferior overall survival in conversion to MRD-positive status 1 those randomized to RIC. This study year after treatment) in previously provides evidence that intervention for untreated pts with CLL and comorbidi- AML patients with MRD can result in ties, translating into improved PFS. improved survival. 15 Annual Meeting of the American Society of Clinical Oncology

Cancer experts - more than 33100 professionals - from around the world are gathering to share the latest clinical cancer research - > 2400 accepted abstracts - impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pan- creatic, prostate, and pediatric cancers, as well as new approaches to overcoming limited access to cancer care, are among the topics that will be highlighted. The theme of this year’s conference is caring for Every Patient, learning from every Patient.

Important studies are usually presen- ted at ASCO press briefings. Oncoletter attended these briefings and recorded the presentations, which are now available at oncoletters website. Just klick the link below the press release.

ASCO›s press releases Mai 15: | Abstract 520: Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial. Read the full release

| Abstract 10009: Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Read the full release

| Abstract 10011: Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. Bild: Thomas Ferber© Read the full release Chicago River

| Abstract 4006: Optimizing chemothera- longer OS than ET alone in premeno- | Abstract LBA4007: Pembrolizumab py for frail and elderly patients with pausal pts with HR+/HER2− ABC. This is with or without chemotherapy versus advanced gastroesophageal cancer the first time that a CDK4/6 inhibitor or chemotherapy for advanced gastric or (aGOAC): The GO2 phase III trial. any targeted agent + ET has demonstra- gastroesophageal junction (G/GEJ) No release available any more ted significantly longer OS vs ET alone adenocarcinoma: The phase 3 KEYNOTE- as initial endocrine-based therapy. 062 study. | Abstract 8001: E3A06: Randomized Clinical trial information: NCT02278120 phase III trial of lenalidomide versus Conclusions: As 1L therapy for advan- observation alone in patients with CLICK TO SEE FULL TEXT of PRESS ced GC, P was noninferior to C for OS in asymptomatic high risk smoldering RELEASE including ABSTRACT CPS ≥1 with clinically meaningful multiple myeloma. WEBCAST improvement for OS in CPS ≥10. P+C did Read the full release not show superior OS and PFS in CPS | Abstract LBA9015: Five-year long-term ≥1 and OS in CPS ≥10. The safety profile Saturday June 1 Press Briefing overall survival for patients with advanced was more favorable for P vs C. Clinical | Announcement: Minimal Common NSCLC treated with pembrolizumab: trial information: NCT02494583 Oncology Data Elements (mCODETM), a Results from KEYNOTE-001. collaboration between ASCO®, the MITRE CLICK TO SEE FULL TEXT of PRESS Corporation, and the Alliance for Clinical Conclusions: In KEYNOTE-001, 5-y OS RELEASE including ABSTRACT Trials in Oncology Foundation. rate was 23.2% in treatment-naive pts WEBCAST and 15.5% in previously treated pts with CLICK TO SEE FULL TEXT of PRESS advanced NSCLC treated with pembro, Sunday June 2 Press Briefing RELEASE including ABSTRACT compared to a historical rate of ~5% | Abstract LBA5563 Earlier Ovarian WEBCAST (per SEER 2008–2014), prior to the Cancer Diagnoses and Treatment Seen introduction of anti–PD-1 therapy. 5-y After ACA Implementation. | Abstract LBA1008: Phase III MONA- OS rate was at least 25% in pts with LEESA- 7 trial of premenopausal patients PD-L1 TPS ≥50% in both pt populations Conclusions: Under the Affordable Care withHR+/HER2− advanced breast cancer in KEYNOTE-001. Clinical trial informa- Act, women with ovarian cancer were (ABC) treated with endocrine therapy ± tion: NCT01295827 more likely to be diagnosed at an early ribociclib: Overall survival (OS) results. CLICK TO SEE FULL TEXT of PRESS stage and receive treatment within 30 Conclusions: RIB + ET demonstrated a RELEASE including ABSTRACT days of diagnosis. As stage and treat- clinically and statistically significant WEBCAST ment are major determinants of 16 Continued: ASCO Annual Meeting 2019

survival, these gains under the ACA may | Abstract LBA4: Maintenance Therapy | Abstract LBA4505: Novel Targeted- have long-term impacts on women with With PARP Inhibitor Olaparib Delays Antibody Treatment Produced Responses ovarian cancer. Progression of BRCA-Related Pancreatic in Nearly Half of Patients With Advanced CLICK TO SEE FULL TEXT of PRESS Cancer. Urothelial Cancer. RELEASE including ABSTRACT WEBCAST Conclusions: Maintenance olaparib Conclusions: Preliminary results from provided a statistically significant and this EV pivotal study demonstrated a | Abstract LBA107: Private Insurance, clinically meaningful improvement in clinically meaningful ORR, consistent Higher Regional Incomes, and Certain PFS in mPC pts with a gBRCAm who with the phase 1 trial, in la/mUC pts Practice Settings Predict Longer Survival had not progressed on PBC. Safety was with prior platinum and CPI, including for People With Multiple Myeloma. consistent with the known profile for LM pts, where there is a high unmet olaparib. POLO is the first phase III trial need. EV was well tolerated with a CLICK TO SEE FULL TEXT of PRESS to validate a biomarker-driven treat- manageable safety profile in these pts. RELEASE including ABSTRACT ment in PC. Clinical trial information: Updated data, including duration of WEBCAST NCT02184195 response, PFS, and OS will be presen- ted. Clinical trial information: Conclusions: Insurance type and CLICK TO SEE FULL TEXT of PRESS NCT03219333 regional income are associated with MM RELEASE including ABSTRACT survival. This may be related to afforda- WEBCAST CLICK TO SEE FULL TEXT of PRESS bility of OAM and merits further RELEASE including ABSTRACT investigation. The following articles were published on WEBCAST NEJM.org to coincide with a meeting of | Abstract LBA1: Racial Disparities in the American Society of Clinical | Abstract LBA10502: Over 60 Percent of Access to Timely Cancer Treatment Oncology. ORIGINAL ARTICLE: Gynecologic Oncologists Say They Have Nearly Eliminated in States With Medicaid Maintenance Olaparib for Germline Experienced Sexual Harassment. Expansion. BRCA-Mutated Metastatic Pancreatic Cancer T. Golan and Others Conclusions: This report is the first to Conclusions: Implementation of show that experience of sexual harass- Medicaid expansions as part of the ACA Monday June 3 Press Briefing: ment is common among Gyn-Onc differentially improved African American | Abstract LBA108: Use of Broader physicians. Importantly, only few report cancer pts’ receipt of timely treatment, Criteria for Clinical Trial Enrollment these occurrences, often for fear of reducing racial disparities in access to Would Double Number of Eligible Patients reprisal or concern that nothing will be care. With Lung Cancer. done. Further, female Gyn-Oncologists report feeling that gender influences CLICK TO SEE FULL TEXT of PRESS Conclusions: Use of the ASCO-Friends salaries and career advancement. RELEASE including ABSTRACT expanded criteria would enable nearly Awareness and acknowledgement of WEBCAST twice as many aNSCLC pts to be sexual harassment and gender inequa- considered for trial participation (4,851 lities within Gyn-Onc can lead to | Abstract LBA2: Adding Enzalutamide to patients, 46.2%). Narrower criteria interventions to address these dispari- Standard First-Line Treatment Improves should only be used based on compel- ties. Survival for Men With Metastatic Hormo- ling scientific rationale for exclusion. CLICK TO SEE FULL TEXT of PRESS ne-Sensitive Prostate Cancer. RELEASE including ABSTRACT CLICK TO SEE FULL TEXT of PRESS WEBCAST Conclusions: ENZA significantly RELEASE including ABSTRACT improved OS when added to SOC in WEBCAST mHSPC. The benefits appeared lower in ASCO DAILY NEWS those planned to receive early DOC. | Abstract LBA3516: Colorectal Cancer Results of analyses with updated Patients With Liver Metastases Live Just Tuesday Highlights of the Day follow-up triggered by this IA will be as Long After Laparoscopic Surgery as Monday Highlights of the Day presented. Clinical trial information: Open Surgery. Sunday Highlights of the Day NCT02446405 Saturday Coverage The Summary includes updated data, CLICK TO SEE FULL TEXT of PRESS not in the abstract RELEASE including ABSTRACT WEBCAST Conclusions: Laparoscopic surgery in patients with colorectal liver metastases The following articles were published on was associated with rates of OS and NEJM.org to coincide with a meeting of RFS similar to open surgery. Clinical the American Society of Clinical trial information: NCT01516710 Oncology. ORIGINAL ARTICLE: Enzalutamide with Standard First-Line CLICK TO SEE FULL TEXT of PRESS Therapy in Metastatic Prostate Cancer RELEASE including ABSTRACT Bild: Thomas Ferber© I.D. Davis and Others WEBCAST John Hancock Center, Chicago

17 Continued: ASCO Annual Meeting 2019

In Zusammenarbeit mit Brustkrebs Deutschland e.V. wurden am ASCO mehrere More abstracts may be found in the Interviews und ein Live Round-Table realisiert. Die Interviews wurden von der following fields: Vorsitzenden des Vereins, Renate Haidinger, München, durchgeführt. Haidinger moderierte auch das Round-Table, das wie immer live stattfand und am 13. Dezem- • Colon Cancer ber 12 Uhr Ortszeit in San Antonio, TX, (19 Uhr CH-Zeit) anlässliches des SABCS • Other Gastrointestinal Cancer erneut stattfindet. Interviews und Round-Table zusammen ergeben eine praktisch vollständige Übersicht, was an wichtigen Studien zum Brustkrebs am ASCO vorgestellt wurde. Alle weiterführenden Links zu den Webcasts HIER • Other Gynaecologic Cancers Statements Sven Mahner & Christian Kurzeder:

• Head & Neck Cancers Statement PD Dr. med. Dr. phil. Sacha Rothschild: wichtige Ergebnisse vom ASCO

• Lung Cancer Statement PD Dr. med. Dr. phil. Sacha Rothschild: wichtige Ergebnisse vom ASCO

• Melanoma Statement Prof. Dr. med. Reinhard Dummer

• Urogenital Cancers LINK

Hematology: • Multiple Myeloma & Myelofibrosis e.g.: Iberdomide; FORTE trial; MAIA; IsaPd; POLLUX update; JAKARTA-2 study

• Lymphoma & CLL VenG; MAGNIFY; AUGMENT; TRANSCEND NHL 001

• ALL Bild: Thomas Ferber©

See you @ next ASCO in Chicago, May 29 - Jun 2, 2020 „Ich brauche jetzt eine neue Chance!“

NEU: CYRAMZA® (Ramucirumab) per 1. Oktober 2019 auch für die Indikation bei metastasierendem Kolorektalkarzinom erstattet2

CYRAMZA® + FOLFIRI: eine Option für die 2. Linie Behandlung von CRC1 Behandlung1A Empfehlung von ESMO CRC Guidelines4 1A Empfehlung ESMO Guidelines5

MEDIAN OS CYRAMZA® + FOLFIRI: Signifikante Verlängerung des Gesamtüberlebens3 CYRAMZA + FOLFORI 13,3 OS Months

Placebo + FOLFORI 11,7 Months

Daten der Zulassungstudie RAISE (N = 1.072 Patienten)

CYRAMZA® bereits für die 2. Linie Behandlung von fortgeschrittener Magenkrebs zugelassen1 und erstattet2 1A Empfehlung ESMO Guidelines5

Eli Lilly (Suisse) SA, Ch. des Coquelicots 16, CP 580, 1214 Vernier (GE)

20 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch

KONGRESSKALENDER 2019 AUSGABEN-VORSCHAU

NOV Genitourinary Cancers Zuversicht in die Zukunft» Advanced Breast Symposium 26. März 2020 - Bern Cancer (ABC5) Feb 13-15, 2020 Fifth ESO-ESMO San Francisco, CA APR ESMO 2019 Congress International Consensus ELCC 2020 – Lung Conference 34. Deutscher Krebs- Cancer Sep 27 - Oct 1, Barcelona, Spain 14 -16 November 2019 kongress 2020 Apr 15-18, 2020 Lisbon, Portugal 19.-22. Februar, 2020 Geneva, Switzerland Bericht folgt Ende November 2019 Berlin, Deutschland DEC 24. Internationales 61st ASH Annual 30. Ärzte-Fortbildungs- Seminar Palliativbe- Meeting and Exposition kurs in Klin. Onkologie treuung von Tumor- 61st ASH Annual Meeting December 7-10, 2019 27. – 29. Februar, 2020 kranken and Exposition Orlando, FL, USA St. Gallen 23. – 25. April 2020 Kartause Ittgen, Warth Dec 7 - 10, 2019 - Orlando, FL 42nd Annual SABCS MAR December 10-14, 2019 TAT 2020 – Targeted AACR Annual Meeting Bericht folgt Ende Januar 2020 San Antonio, Texas, USA Anticancer Therapies April 24-29, 2020 March 2-4, 2020 San Diego, California JAN - FEB Paris, France SABCS 2nd Zurich Brain MAY Metastasis Symposium SAMO Masterclass I SENOLOGIE & LIVE Dec 10 - 14, 2019 , San Antonio, TX 16.01.2020 - 17.01.2020 March 3 2020 SURGERY update 2020 Zurich, UniversityHospi- CH-3011 Bern May 2020 (date TBA) Bericht folgt Ende Januar 2020 tal Zürich/Switzerland 12th European Breast Gastrointestinal Cancer Conference SAKK Halbjahresver- Cancers Symposium (EBCC-12) sammlung Jan 23-25, 2020 March 18-20, 2020 13.- 15. Mai, 2020 San Francisco, CA Barcelona, Spain Zürich, Hotel Marriott

EHA-EBMT 2nd St. Gallen International JUN-JUL European CAR T Cell Gastrointestinal Cancer ASCO Annual Meeting Meeting Conference May 29 - Jun 2, 2020| Jan 30 – Feb 1, 2020 Focus on Oligometas- Chicago, Illinois Sitges, Spain tatic Disease - Under the auspices of EORTC The 25th EHA Annual SAMO Interdisciplinary March 19-21, 2020 Congress Workshop on Radio-/ St. Gallen Switzerland June 11-14, 2020 Chemo-/Immuno-The- Frankfurt, Germany rapy 2020 Annual EAU Congress 31.1.-1.2.2020 March 20-24, 2020 40. Jahrestagung der Lucerne/Switzerland Amsterdam, NL Deutschen Gesell- schafts für Senologie ESMO Sarcoma & GIST 46th Annual Meeting of 25.-27. Juni, 2020 Conference 2020 the European Society München, Deutschland Feb 3-5 Feb 2020 for Blood and Marrow , Italy Transplantation MASCC/ISOO 2020 March 22-25, 2020 Cancer Care Annual KONTAKT SCO-SITC Clinical Madrid, Spain Meeting on Supportive Immuno-Oncology Care in Cancer Oncoletter Symposium 22. Schweizer Onkolo- 25-27 June, 2020 Dr. med. Thomas Ferber FEB 6 - 8, 2020 giepflege Kongress Sevilla, Spain Postfach 412 Orlando, Florida «Mit Inspiration und CH-8201 Schaffhausen Mail: info [@] oncoletter.ch

Oncoletter ist für Ärztinnen und Ärzte sowie medizinisches Fachpersonal bestimmt. Oncoletter kann hierfür von einer nicht öffentlich zugänglichen Webseite heruntergeladen werden